References of "Jansen, Nicolas"
     in
Bookmark and Share    
Full Text
See detailReimbursement of radiotherapy in Belgium
JANSEN, Nicolas ULg

Conference (2012, April 26)

The author gives an overview of the proposals for a new reimbursement system for radiotherapy in Belgium, to be possibly introduced in 2013.

Detailed reference viewed: 8 (0 ULg)
Full Text
See detailLe futur centre intégré d'oncologie de Liège (CIO) : analyse des besoins de l'équipe de radiothérapie-oncologie. L'application des principes de 'healing environment'
JANSEN, Nicolas ULg

Conference given outside the academic context (2012)

Dans le cadre des projets futurs du CHU de Liege de construire un 'Centre Intégré d'Oncologie', les besoins du service de radiothérapie ont été analysés et documentés. Les points importants ont été ... [more ▼]

Dans le cadre des projets futurs du CHU de Liege de construire un 'Centre Intégré d'Oncologie', les besoins du service de radiothérapie ont été analysés et documentés. Les points importants ont été soulignés, comme entre autres la surface nécessaire, l'évolution rapide de la radiothérapie, le concept de 'healing environment', le cout potentiel, l'importance de la circulation, la communication avec le monde externe, ... [less ▲]

Detailed reference viewed: 53 (13 ULg)
Full Text
See detaily a-t-il une place pour la radiothérapie en fin de vie ?
BARTHELEMY, Nicole ULg; JANSEN, Nicolas ULg; GENNIGENS, Christine ULg et al

in Revue Médicale de Liège (2012), 67(3), 128132

Près de 50 % des patients atteints d’un cancer bénéficient, à un moment de leur trajet de soins, d’une irradiation. Celle-ci peut être administrée avec une intention curative ou palliative, en fonction de ... [more ▼]

Près de 50 % des patients atteints d’un cancer bénéficient, à un moment de leur trajet de soins, d’une irradiation. Celle-ci peut être administrée avec une intention curative ou palliative, en fonction de l’extension de la maladie, de l’état général du patient et de sa volonté. Le but d’une irradiation palliative, sera de contrôler localement la tumeur ou la métastase et, donc, de ralentir l’évolution du cancer. La radiothérapie peut également être utile pour supprimer un symptôme et, ainsi, être un des traitements de confort en fin de vie. La dose totale, la dose par fraction ainsi que la technique d’irradiation sont adaptées à l’intention du traitement. Cet article passe en revue les principales indications d’irradiation en fin de vie. [less ▲]

Detailed reference viewed: 26 (1 ULg)
Full Text
See detailCyberknife et pathologies bénignes
LALLEMAND, François ULg; JANVARY, Zsolt Levente ULg; JANSEN, Nicolas ULg et al

in Revue Médicale de Liège (2011), 66(11), 568-574

Conventional radiotherapy is known to be an effective treatment approach even for “benign” pathologies. However, this kind of treatment yields a high potential for side effects. The Cyberknife®, a robotic ... [more ▼]

Conventional radiotherapy is known to be an effective treatment approach even for “benign” pathologies. However, this kind of treatment yields a high potential for side effects. The Cyberknife®, a robotic stereotactic radiotherapy device, enables to offset a large proportion of the disadvantages encountered with conventional radiotherapy essentially through the high precision of dose administration and sparing of healthy tissues. Therefore, it seems to be a treatment of choice in the approach of some benign intracranial diseases. We review published data on indications and outcome of Cyberknife® for intracranial “non-malignant” disease. [less ▲]

Detailed reference viewed: 27 (2 ULg)
Full Text
See detailCyberknife for lung tumors : the first Belgian experience at CHU Liege and initiated research projects
JANSEN, Nicolas ULg; COUCKE, Philippe ULg

Conference (2011, October 15)

Results are presented of the first Belgian Cyberknfe experience (robotic stereotactic radiotherapy of early lung cancer). Future research projects are detailed : (1) cost analysis (2) comparative ... [more ▼]

Results are presented of the first Belgian Cyberknfe experience (robotic stereotactic radiotherapy of early lung cancer). Future research projects are detailed : (1) cost analysis (2) comparative dosimetry (3) predictive markers for response [less ▲]

Detailed reference viewed: 11 (0 ULg)
Full Text
See detailStereotactic Cyberknife based radiotherapy: introduction and possible dosimetric comparisons with other treatment techniques
JANSEN, Nicolas ULg

Scientific conference (2011, April 29)

After an introduction concerning medical aspects of the stereotactic robotic radiotherapy system 'Cyberknife', different possibilities are presented to compare this technical approach to other ... [more ▼]

After an introduction concerning medical aspects of the stereotactic robotic radiotherapy system 'Cyberknife', different possibilities are presented to compare this technical approach to other radiotherapy systems. Specifically dosimetric comparisons are discussed, and pitfalls in doing so. [less ▲]

Detailed reference viewed: 14 (1 ULg)
Full Text
See detailLa radiothérapie des cancers urologiques : cours d'introduction pour l'ensemble des intervénants médicaux et non-médicaux.
JANSEN, Nicolas ULg; SOBCZAK, Sonia ULg; RUYANGE, Bishaka Willy ULg et al

Learning material (2011)

Une introduction concernant la radiothérapie des néoplasies urologiques : tumeurs rénales, de l'ureter, de la vessie, de l'urèthre, de la verge, de la prostate, et des testicules.

Detailed reference viewed: 8 (3 ULg)
Full Text
See detailAi-je bien entendu ? Je peux me faire traiter autrement que par chirurgie pour mon schwannome de l’acoustique
COUCKE, Philippe ULg; JANVARY, Zsolt Levente ULg; BAART, Véronique ULg et al

in Revue Médicale de Liège (2011), 66(10), 521-528

L’histoire du schwannome du nerf acoustique (SV) montre un déplacement du «standard de traitement» de la microchirurgie vers la radiothérapie. Pour ce type de tumeurs bénignes, le traitement a pour but ... [more ▼]

L’histoire du schwannome du nerf acoustique (SV) montre un déplacement du «standard de traitement» de la microchirurgie vers la radiothérapie. Pour ce type de tumeurs bénignes, le traitement a pour but d’éviter les complications fonctionnelles et de préserver la capacité auditive. Après microchirurgie pour une lésion de moins de 25 mm, on observera que le nerf facial est indemne dans approximativement 60% des cas et que la fonctionnalité du VIII est préservée dans 15% des cas pour des SV de plus de 15 mm et, dans 50% des cas, pour des SV de moins de 15 mm. Les différents progrès techniques et informatiques dans le domaine de la radiothérapie permettent aujourd’hui d’obtenir un taux de contrôle tumoral variant de 92 à 98% avec une morbidité quasi inexistante au niveau du nerf facial (<2%). La capacité auditive est maintenue dans approximativement 70% des cas. Forts de ces chiffres, on peut estimer que la prise en charge de ce type de tumeurs bénignes doit se faire par radiothérapie. [less ▲]

Detailed reference viewed: 22 (5 ULg)
Full Text
See detailAccelerated partial breast irradiation: state of the art
COUCKE, Philippe ULg; JANSEN, Nicolas ULg; JANVARY, Zsolt Levente ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2011), 5(1), 3-7

Accelerated partial breast irradiation can be applied by means of different techniques. It <br />offers an opportunity for reducing the treatment duration considerably and harbours the <br />potential for ... [more ▼]

Accelerated partial breast irradiation can be applied by means of different techniques. It <br />offers an opportunity for reducing the treatment duration considerably and harbours the <br />potential for less exposure of healthy tissue to higher radiation doses. However, evidence <br />issued from randomized trials is limited. European and American experts call our attention <br />to the potential dangers of widespread implementation of these techniques without any <br />long-term data on outcome and ask for complete information of patients on the potential <br />hazards and risks if accelerated partial breast irradiation is used instead of whole breast <br />irradiation. [less ▲]

Detailed reference viewed: 40 (7 ULg)
Full Text
See detailNew indications for radiotherapy: primary liver cancer and secondary liver oligometastases
JANVARY, Zsolt Levente ULg; JANSEN, Nicolas ULg; MARTINIVE, Philippe ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2011), 5(1), 8-13

Surgery is considered to be the standard treatment for intrahepatic malignancies, primary <br />cancers and metastatic lesions. However, a great many patients are not eligible for surgical <br ... [more ▼]

Surgery is considered to be the standard treatment for intrahepatic malignancies, primary <br />cancers and metastatic lesions. However, a great many patients are not eligible for surgical <br />intervention. Modern stereotactic radiotherapy has the potential to be an effective alternative <br />treatment modality with low toxicity for patients with primary hepatocellular carcinoma <br />and liver oligometastases. In this paper we intend to review the current status and published <br />experiences in the field of liver irradiation. [less ▲]

Detailed reference viewed: 42 (4 ULg)
Full Text
See detailFirst study of oral artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers
Jansen, Frans Herwig; Adoubi, Innocent; Kouassi, Comoe J.C. et al

in Anticancer Research (2011), 31(12), 4417-4422

Background/Aim: Artenimol-R is cytotoxic in transformed cervical cells and safety in humans is yet to be established. The present study investigates the clinical benefits, safety and the tumor marker ... [more ▼]

Background/Aim: Artenimol-R is cytotoxic in transformed cervical cells and safety in humans is yet to be established. The present study investigates the clinical benefits, safety and the tumor marker effect of orally administered Artenimol-R in patients with advanced cervix carcinoma. Patients and Methods: Ten patients were treated with Artenimol-R for 28 days. Clinical symptoms, vaginal discharge and pain were followed-up. Adverse events were recorded. Biopsy samples were analyzed by immunohistochemistry for the expression of relevant tumor markers. Results: Artenimol-R treatment induced clinical remission with a median time for the disappearance of the symptoms being 7 days. No adverse events of grade 3 or 4 occurred. The expression of p53, Epidermal growth factor receptor (EGFR), and antigen Ki-67 as a cellular marker of proliferation, as well as the number of blood vessels stained by the CD31 antibody decreased, whereas the expression of transferrin receptor protein 1 (CD71) increased. Conclusion: The current pilot study provides evidence on the improvement of the clinical symptoms and the good tolerability of Artenimol-R in patients with advanced carcinoma of the cervix uteri. A survival trial with Artenimol- R in advanced patients is warranted. [less ▲]

Detailed reference viewed: 20 (2 ULg)
Full Text
See detailEVALUATION OF THE AUTOMATIC IMAGE REGISTRATION FEATURES OF A KV CONE-BEAM CT IMAGING SYSTEM
JANVARY, Zsolt Levente ULg; JANSEN, Nicolas ULg; MATHOT, Michel ULg et al

in Radiotherapy & Oncology (2010), 96(supp 1),

Detailed reference viewed: 16 (2 ULg)
Full Text
See detailEVALUATION OF THE AUTOMATIC IMAGE REGISTRATION FEATURES OF A KV CONE-BEAM CT IMAGING SYSTEM
JANVARY, Zsolt Levente ULg; JANSEN, Nicolas ULg; MATHOT, Michel ULg et al

Poster (2010, September)

As a part of the clinical implementation of a kV cone-beam CT (CBCT) volumetric imaging system for new Elekta Synergy linear accelerators, the automatic image registration (IR) system of the XVI Software ... [more ▼]

As a part of the clinical implementation of a kV cone-beam CT (CBCT) volumetric imaging system for new Elekta Synergy linear accelerators, the automatic image registration (IR) system of the XVI Software was studied. We examined the effect of the variability of matching parameters of the software on the results of the patient position errors. [less ▲]

Detailed reference viewed: 16 (2 ULg)
Full Text
See detailExperience feed back committee (EFBC) in radiotherapy
DELGAUDINE, Marie ULg; JANSEN, Nicolas ULg; COUCKE, Philippe ULg

Poster (2010, September)

Radiotherapy is a powerful continuously evolving effective treatment tool. Our aim is to offer the best treatments and assure security for patients and personnel. A proactive quality approach copied from ... [more ▼]

Radiotherapy is a powerful continuously evolving effective treatment tool. Our aim is to offer the best treatments and assure security for patients and personnel. A proactive quality approach copied from the one implemented in the air transport industry has been established in our department. An Experience feed back committee (EFBC) has been set up to identify, record and analyze systematically all reported precursor events. Our final objective is to test and strengthen the security of the organization and the quality of care for patients. [less ▲]

Detailed reference viewed: 12 (1 ULg)
Full Text
See detailPourquoi les traitements de radiothérapie adjuvante pour cancer du sein ne comptent-ils plus autant de séances ?
Coucke, Philippe ULg; Jansen, Nicolas ULg; Collignon, Joëlle ULg et al

in Revue Médicale de Liège (2010), 65(1), 10-14

La radiothérapie adjuvante postopératoire pour cancer du sein compte habituellement vingt-cinq séances de radiothérapie auxquelles on ajoute une surimpression centrée sur le lit tumoral. Dans le contexte ... [more ▼]

La radiothérapie adjuvante postopératoire pour cancer du sein compte habituellement vingt-cinq séances de radiothérapie auxquelles on ajoute une surimpression centrée sur le lit tumoral. Dans le contexte d’une augmentation progressive et continue de la charge de travail et afin de réduire les contraintes humaines et techniques, une radiothérapie plus courte est aujourd’hui utilisée. Ces schémas hypo-fractionnés sont validés par des essais randomisés et publiés. Sur la base de ces publications, un nouvel arbre décisionnel a été établi qui permet d’obtenir des résultats équivalents en contrôle local tout en gardant un taux de complications comparable, voire même inférieur au schéma classique [less ▲]

Detailed reference viewed: 87 (7 ULg)
Full Text
See detailVers une radiothérapie chirurgicale :nécessité d’une radiothérapie guidée par l’imagerie
COUCKE, Philippe ULg; WITHOFS, Nadia ULg; JANSEN, Nicolas ULg et al

in Revue Médicale de Liège (2010), 65(supp 1), 17-22

résumé : L’évolution extrêmement rapide en robotique et en informatique a permis l’avènement de techniques telles que le CcyberKnife®, capables d’appliquer en radiothérapie des doses dites «ablatives» et ... [more ▼]

résumé : L’évolution extrêmement rapide en robotique et en informatique a permis l’avènement de techniques telles que le CcyberKnife®, capables d’appliquer en radiothérapie des doses dites «ablatives» et ceci avec une précision chirurgicale. Ce type de traitement ablatif n’est pas réellement concevable avec des techniques conventionnelles en radiothérapie et des changements <br />majeurs de paradigmes ont eu lieu, particulièrement dans la méthodologie de définition de la cible et des marges ainsi que dans la manière dont on fractionne le traitement. Ggrâce à ces changements, on est à même de proposer aux patients des traitements <br />qui représentent un doublement au niveau de l’efficacité <br />biologique. Ppour obtenir une couverture optimale au niveau de la cible, tout en évitant les structures saines avoisinantes, il est donc impératif d’obtenir la meilleure définition possible de la cible tant au niveau de la l’extension de la lésion qu’au niveau de son «contenu», c’est-à-dire les caractéristiques métaboliques et fonctionnelles. Lla révolution technologique en cours dans le monde de l’imagerie métabolique et fonctionnelle va permettre d’utiliser l’information numérisée pour individualiser les traitements <br />et les adapter aux caractéristiques mêmes de la lésion ainsi qu’à son évolution au décours du traitement. [less ▲]

Detailed reference viewed: 65 (3 ULg)
Full Text
See detailA dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy
Hermesse, Johanne ULg; Biver, Sylvie; JANSEN, Nicolas ULg et al

in Strahlentherapie und Onkologie (2009), 185(11), 736-742

Background and Purpose: Dose escalation in order to improve the biochemical control in prostate cancer requires the application of irradiation techniques with high conformality. The dosimetric selectivity ... [more ▼]

Background and Purpose: Dose escalation in order to improve the biochemical control in prostate cancer requires the application of irradiation techniques with high conformality. The dosimetric selectivity of three radiation modalities is compared: high-dose-rate brachytherapy (HDR-BT), intensity-modulated radiation radiotherapy (IMRT), and helical tomotherapy (HT). <br />Patients and Methods: Ten patients with prostate adenocarcinoma treated by a 10-Gy HDR-BT boost after external-beam radiotherapy were investigated. For each patient, HDR-BT, IMRT and HT theoretical treatment plans were realized using common contour sets. A 10-Gy dose was prescribed to the planning target volume (PTV). The PTVs and critical organs’ dose-volume histograms obtained were compared using Student’s t-test. <br />Results: HDR-BT delivers spontaneously higher mean doses to the PTV with smaller cold spots compared to IMRT and HT. 33% of the rectal volume received a mean HDR-BT dose of 3.86 ± 0.3 Gy in comparison with a mean IMRT dose of 6.57 ± 0.68 Gy and a mean HT dose of 5.58 ± 0.71 Gy (p < 0.0001). HDR-BT also enables to better spare the bladder. The hot spots inside the urethra are greater with HDR-BT. The volume of healthy tissue receiving 10% of the prescribed dose is reduced at least by a factor of 8 with HDR-BT (p < 0.0001). <br />Conclusion: HDR-BT offers better conformality in comparison with HT and IMRT and reduces the volume of healthy tissue receiving a low dose. [less ▲]

Detailed reference viewed: 97 (22 ULg)
Full Text
See detailLe cas clinique du mois. Reaction de rappel d'irradiation induite par l'administration de cyclophosphamide.
Mievis, Carole ULg; Jansen, Nicolas ULg; Schleich, FLorence ULg et al

in Revue Médicale de Liège (2009), 64(4), 179-81

Radiation recall dermatitis is an inflammatory skin reaction occurring in a previously irradiated field following the delivery of a promoting agent. It has been described after a number of antineoplastic ... [more ▼]

Radiation recall dermatitis is an inflammatory skin reaction occurring in a previously irradiated field following the delivery of a promoting agent. It has been described after a number of antineoplastic agents such as gemcitabine, taxanes, anthracyclines. We report the case of a 50-year-old man with metastatic prostate cancer who developed two consecutive radiation recall dermatitis episodes triggered by oral cyclophosphamide. They occurred 4 to 5 weeks after palliative radiotherapy on bone metastasis. Spontaneous resolution was observed within 6 weeks after discontinuation of cyclophosphamide and with local supportive care. To our knowledge this is the first reported case of radiation recall dermatitis after oral cyclophosphamide. [less ▲]

Detailed reference viewed: 80 (7 ULg)